Lyell Immunopharma Q2 Adj $(0.18) Beats $(0.20) Estimate, Sales $13.00K Down From $27.00K YoY
Portfolio Pulse from Benzinga Newsdesk
Lyell Immunopharma (NASDAQ:LYEL) reported Q2 losses of $(0.18) per share, beating the analyst estimate of $(0.20). However, sales dropped to $13.00K from $27.00K YoY.
August 07, 2024 | 9:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lyell Immunopharma reported Q2 losses of $(0.18) per share, beating the analyst estimate of $(0.20). However, sales dropped significantly to $13.00K from $27.00K YoY.
While LYEL beat the earnings estimate, the significant drop in sales is concerning. The mixed results may lead to neutral short-term price movement as investors weigh the earnings beat against the revenue decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100